Fingolimod Formulation Stabilization via Cyclodextrin Inclusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a stable, homogeneous, and uniformly composed oral pharmaceutical formulation containing a low amount of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, which is challenging due to fingolimod's instability with excipients and tendency to segregate, especially at high temperatures or humidity, making it difficult to maintain therapeutic efficacy with low drug content.
Innovation Solution
Incorporating a cyclodextrin as a stabilizer and filler such as mannitol, along with optional binders and lubricants, to create a solid composition that ensures uniform particle size and distribution of the active ingredient, minimizing segregation and degradation, thereby achieving stability and content uniformity even at low drug concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a low amount of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol is used in the composition, then the therapeutic efficacy is maintained with reduced side effects, but the composition becomes unstable and shows poor content uniformity
Solution Approach 1:
Cyclodextrin is used as a stabilizing agent and intermediary substance that forms an inclusion complex with 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol. This complexation protects the active ingredient from degradation and maintains composition stability even at low drug concentrations (0.5 mg or less per dosage unit), thereby preserving therapeutic efficacy while improving formulation stability.
2Productivity
If 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol is micronized to improve dissolution, then the bioavailability is enhanced, but the compound becomes static and segregates during manufacturing
Solution Approach 1:
Cyclodextrin acts as a mediating substance that forms a stable inclusion complex with micronized 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol. This complexation prevents the static nature and adhesion to metal surfaces that cause segregation during manufacturing, while maintaining the enhanced dissolution properties provided by micronization.
Solution Approach 2:
The formulation creates a composite material system where cyclodextrin and 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol form an inclusion complex. This composite structure combines the benefits of micronization (improved dissolution) with the stabilizing properties of cyclodextrin, preventing segregation during manufacturing processes.
3Ease of operation
If fingolimod is mixed with excipients to form a solid composition, then the oral administration is enabled, but degradation products are formed at unacceptable levels
Solution Approach 1:
Cyclodextrin serves as a protective intermediary that forms an inclusion complex with fingolimod, shielding it from interactions with excipients that would otherwise cause degradation. This enables the formulation to be suitable for oral administration while maintaining degradation products below acceptable thresholds.
Solution Approach 2:
The cyclodextrin inclusion complex creates a protected, inert microenvironment around the fingolimod molecule, isolating it from reactive excipients and preventing degradation reactions. This allows the composition to be stable and suitable for oral administration without forming unacceptable levels of degradation products.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of cyclodextrin and mannitol in the formulation results in a stable, physically stable composition with appropriate content uniformity, reducing segregation and degradation, allowing for effective administration of low doses of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, ensuring consistent therapeutic benefit.
Implementation Method 1
WO 2005/025553 A2 discloses in one embodiment FTY720 in combination with a stabilizer, such as cyclodextrin
Implementation Method 2
Incorporating a cyclodextrin as a stabilizer and filler such as mannitol, along with optional binders and lubricants, to create a solid composition that ensures uniform particle size and distribution of the active ingredient
Data Source
AI summary
A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.